Baxter is an American multinational healthcare company that is recognized for M&A in the 2022 Medical Device Network Excellence Awards.

Recently the American multinational has been expanding, mainly in the field of digital health and invasive devices. The company has been engaged in some notable collaborations in the medical device RnD scene too.

With the acquisition of Hill-Rom, the company is aiming to expand its presence mainly in the connected care devices market, but the American multinational will also benefit from Hill-Rom’s expertise in monitoring, diagnostics and blood purification.

Baxter has also acquired some PerClot assets from CryoLife with the aim of diversifying its surgery portfolio with new active and passive solutions. 

Notably, the company has been collaborating with bioMérieux to launch a new kidney injury prediction test that allows clinicians to develop personalised treatments for patients.

Company Profile

Baxter is a provider of a range of healthcare products. Its product and service offerings include dialysis in acute and chronic conditions, sterile intravenous solutions, generic injectable pharmaceuticals, parenteral nutrition therapies, infusion systems and devices, inhaled anaesthetics, and surgical hemostat and sealant products. 

The company’s products find application in hospitals, rehabilitation centres, kidney dialysis centres, nursing homes, and patients at home. Baxter distributes its products through direct sales force and a network of independent distributors, drug wholesalers, specialty pharmacies and other alternative site providers. 

The company has operations in the Americas, the Middle East, Africa, Europe and Asia-Pacific. Baxter is headquartered in Deerfield, Illinois, the US.